False-positive beta-glucan test due to beta-glucan component in sterile gauze during treatment of fungal sepsis: a case report
By
Yi Wu
Da Ma
Qiling Lin
ChunLei Zhang
May 18, 2026
Clinical Scorecard: Misleading beta-glucan assay results caused by beta-glucan in sterile gauze during fungal sepsis management: a case study
At a Glance
Category Detail
Condition Key Mechanisms Detection of (1,3)-β-D-glucan (BDG) in the bloodstream indicating fungal infection, particularly in the context of contamination. Target Population Care Setting
Key Highlights
False-positive results of the G test can complicate diagnosis and management of IFDs. Contamination from medical sterile gauze can lead to misleading BDG assay results. Clinical improvement does not always correlate with G test results. Clinical correlation is essential when interpreting G test results. Guideline-Based Recommendations
Diagnosis
Consider potential confounding variables when interpreting G test results. Utilize microbiological proof alongside clinical findings for accurate diagnosis. Consult with infectious disease specialists when G test results are ambiguous. Management
Antifungal treatment should not be solely based on G test results. Consider patient history and clinical context when deciding on antifungal therapy. Monitoring & Follow-up
Regularly assess clinical status and inflammatory markers during antifungal therapy. Risks
Misinterpretation of G test results can lead to inappropriate antifungal treatment. Patient & Prescribing Data
Micafungin and caspofungin were used effectively despite misleading G test results, highlighting the need for clinical judgment.
Clinical Best Practices
Conduct thorough evaluations of potential contamination sources for G test results. Integrate clinical judgment with laboratory findings for treatment decisions. Consider patient history and previous infections when interpreting G test results. Related Resources & Content
